Sun denies Ranbaxy deal insider trading suggestions
This article was originally published in Scrip
Executive Summary
Sun Pharma had moved swiftly to clarify that it has not violated insider trading rules, amid suggestions that India's markets regulator may consider a preliminary probe into the significant spike in Ranbaxy's shares on local bourses ahead of its acquisition by Sun.